Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics - Scorecard - MDSpire
Clinical Scorecard: Survival Outcomes After Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Baseline Tumor Features
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Survival Outcomes After Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Baseline Tumor Features
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
344 patients with mCRPC, with prior synchronous (n=198) or metachronous (n=146) mHSPC, treated with Lu-177-PSMA during mCRPC treatment lines 1–7.
Care Setting
Care setting described in the source article.
Key Highlights
The retrospective cohort included 344 patients: 198 with synchronous and 146 with metachronous mHSPC before mCRPC.
The supplied excerpt describes the study methods and cohort characteristics but does not provide PFS or OS results.
Guideline-Based Recommendations
Diagnosis
Study eligibility required PSMA-PET/CT showing PSMA-positive lesions before Lu-177-PSMA treatment.
At the mHSPC stage, M-stage classification was based mainly on CT and bone scan or PSMA-PET/CT. M1b included bone metastases with or without lymph-node metastases; M1c included visceral metastases with or without bone or lymph-node metastases.
Management
At the study center, Lu-177-PSMA was administered every 4–6 weeks using PSMA-617 or PSMA-I&T.
Treatment was administered as individual compassionate use after tumor-board discussion or following EMA approval after ARPI and taxane-based chemotherapy.
Monitoring & Follow-up
PFS was defined from Lu-177-PSMA initiation to a new systemic treatment or death; OS was defined from treatment initiation to death from any cause.
Patients were evaluated and discussed by a multimodal tumor board before and after treatment.
Risks
The supplied excerpt does not report treatment-related adverse events or safety outcomes.
Patient & Prescribing Data
Patients with mCRPC and prior synchronous or metachronous mHSPC treated with Lu-177-PSMA in treatment lines 1–7; median age at mCRPC was 71 years, and the median number of Lu-177-PSMA cycles was 4.
The median number of systemic mCRPC treatment lines was 3. The supplied excerpt does not provide the distribution of Lu-177-PSMA treatment lines.
Clinical Best Practices
Study eligibility required PSMA-positive lesions on PSMA-PET/CT.
Patients were evaluated and discussed by a multimodal tumor board before and after treatment.
The study was a retrospective analysis of patients treated at a single center.
by Mike Wenzel, Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Konrad Klimek, Christian Happel, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Thomas Steuber, Tobias Maurer, Maximilian C. Kriegmair, Pierre I. Karakiewicz, Felix K. H. Chun, Daniel Groener, Philipp Mandel
Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.
